SEC Comment Letter 0000000000-25-003063 to Scienture Holdings, Inc. (SCNX)

Scienture Holdings, Inc.
Date: March 21, 2025 · CIK: 0001382574 · Accession: 0000000000-25-003063

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

March 21, 2025

Author

Division of

Form

UPLOAD

Company

Scienture Holdings, Inc.

Letter

Re: Scienture Holdings, Inc. Draft Registration Statement on Form S-1 Submitted March 18, 2025 CIK No. 0001382574 Dear Surendra Ajjarapu:

March 21, 2025

Surendra Ajjarapu Chief Executive Officer Scienture Holdings, Inc. 6308 Benjamin Rd, Suite 708 Tampa, FL 33634

Our initial review of your draft registration statement indicates that it fails to comply with the requirements of the Securities Act of 1933, the rules and regulations thereunder and the requirements of the form. More specifically, the draft registration statement does not include audited financial statements for the fiscal year ended December 31, 2024.

We will provide more detailed comments relating to your draft registration statement following our review of a substantive amendment that addresses this deficiency.

Please contact Jason Drory at 202-551-8342 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Kate Bechen

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 March 21, 2025

Surendra Ajjarapu
Chief Executive Officer
Scienture Holdings, Inc.
6308 Benjamin Rd, Suite 708
Tampa, FL 33634

 Re: Scienture Holdings, Inc.
 Draft Registration Statement on Form S-1
 Submitted March 18, 2025
 CIK No. 0001382574
Dear Surendra Ajjarapu:

 Our initial review of your draft registration statement indicates that
it fails to comply
with the requirements of the Securities Act of 1933, the rules and regulations
thereunder and
the requirements of the form. More specifically, the draft registration
statement does not
include audited financial statements for the fiscal year ended December 31,
2024.

 We will provide more detailed comments relating to your draft
registration statement
following our review of a substantive amendment that addresses this deficiency.

 Please contact Jason Drory at 202-551-8342 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Kate Bechen
</TEXT>
</DOCUMENT>

SecProbe.io